Seasonal IVIG contains high infectivity neutralizing and hemagglutination inhibition activity against seasonal flu virus strains selected for vaccines (2020-22)
Abstract
IVIG solutions (10%) were tested for infectivity neutralization and hemagglutination inhibition against the influenza strains (two A and two B) recommended by the WHO for inclusion in vaccines for Northern and Southern hemispheres 2020-2022. The IVIG batches used were manufactured (June 2020) from plasma pools collected in the US. Potent neutralization and inhibition of hemagglutination were seen with these IVIG batches. This raises the possibility that IVIG could be added to existing therapies, especially in immunocompromised patients, to fight serious influenza infections. Further study of the potential of IVIG in influenza is warranted.
02 /Specification & Classification
Click any tag to browse matching papers- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Elicitation of broadly protective immunity to influenza by multivalent hemagglutinin nanoparticle vaccines
S. Boyoglu-Barnum, D. Ellis, … M. Kanekiyo·bioRxiv·May 30, 2020
- A single cycle influenza virus coated in H7 hemagglutinin provides heterotypic protection and neutralising antibody responses to both glycoproteins.
T. J. Powell, P. Rijal, … A. R. M. Townsend·bioRxiv·Nov 27, 2017
- A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity
Holly Sadler, Pramila Rijal, … Alain Townsend·Journal of VirologyPeer-reviewed·Jan 27, 2025
- Modernizing the original influenza vaccine to enhance protective antibody responses against neuraminidase antigens
M. Rakic-Martinez, J. Gao, … R. Daniels·bioRxiv·Feb 20, 2023
- Development and use of Lentiviral Vectors Pseudotyped with Influenza B Haemagglutinins: application to vaccine immunogenicity, mAb potency and sero-surveillance studies
Francesca Ferrara, George Carnell, … Nigel J Temperton·bioRxiv·Dec 10, 2018
- Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans
P. Rijal, B. B. Wang, … K.-Y. A. Huang·bioRxiv·Jun 26, 2019